MKI67 and cancer: In a recent paper including 69 patients with NET G3 (primary sites: 46 pancreas, 11 unknown primary cancer, 6 midgut, 3 stomach, 3 rectum) treated with PRRT, PFS was significantly higher (11 vs 4 months) in patients with Ki-67 lower or equal to 55% (n = 53) as compared to G3 with higher Ki-67 levels.